Preview

Научно-практическая ревматология

Расширенный поиск

ЛЕЙКОЦИТОКЛАСТИЧЕСКИЙ ВАСКУЛИТ,СВЯЗАННЫЙ С ЛЕЧЕНИЕМ АДАЛИМУМАБОМБОЛЬНОГО АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ

https://doi.org/10.14412/1995-4484-2010-449

Полный текст:

Аннотация

Описано собственное наблюдение случая развития лейкоцитокластического васкулита у больного анкилозирующим спондили-
том после второй инъекции адалимумаба и приведена литературная справка о случаях васкулита, индуцированного ингибито-
рами фактора некроза опухоли ƒ .

Список литературы

1. <div><p>Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis. Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Arthr Rheum 2006;54:2136-46.</p><p>Van der Heijde D., Pangan A.L., Schiff M.H. et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008;67:1218-21.</p><p>Van der Heijde D., Schiff M.H., Sieper J. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.</p><p>Lambert R.G., Salonen D., Rahman P. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebocontrolled study. Arthr Rheum 2007;56:4005-14.</p><p>Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2005;288 с.</p><p>Miceli-Richard C., Dougados M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002;20(Suppl. 28):65-6.</p><p>Бочкова А.Г. Рекомендации по ведению больных с анкилозирующим спондилитом. По материалам Международной рабочей группы по изучению анкилозирующего спондилита (ASAS Assesment Ankylosing Spondylitis Work Group). Совр ревматол 2009;4:5-10.</p><p>Van der Horst-Bruinsma I.E., Clegg D., Dijkmans B.A. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002;20(Suppl. 28):67-70.</p><p>Dougados M., van der Linden S., Leirisalo-Repo M. et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized multicenter, double-blind, placebocontrolled study. Arthr Rheum 1995;38:618-27.</p><p>Clegg D.O., Reda D.J., Weisman M.H. еt al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs cooperative study. Arthr Rheum 1996;39:2004-12.</p><p>Clegg D.O., Reda D.J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthr Rheum 1999;42:2325-9.</p><p>Braun J., de Keyser F., Brandt J. et al. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.</p><p>Calin A., Dijkmans B.A., Emery P. et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.</p><p>McLeod C., Bagust A., Boland A. et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.</p><p>Ashok D., Dubey S., Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2008;27:261-4.</p><p>Galaria N.A., Werth V.P., Schumacher H.R. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4.</p><p>Brion P.H., Mittal-Henkle A., Kalunian K.C. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999;131:634.</p><p>Mohan N., Edwards E.T., Cupps T.R. et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-8.</p><p>Grunwald M.H., Shriker O., Halevy S. et al. Impaired neutrophil functions in patients with leukocytoclastic vasculitis. Int J Dermatol 1997;36:509-13.</p><p>Koutkia P., Mylonakis E., Rounds S., Erickson A. Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol 2001;30:315-22.</p><p>Claudy A. Pathogenesis of leukocttoclastic vasculitis. Eur J Dermatol 1998;8:75-9.</p><p>Jennette J.C., Falk R.J. Small-vessel vasculitis. New Engl J Med 1997;337:1512-23.</p><p>Ramos-Casals M., Brito-Zero'n P., Mun~oz S. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.</p><p>Saint Marcoux B., De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. J Bone Spine 2006;73:710-3.</p><p>Mueller R., Skapenko A., Grunke M. et al. TNF-alpha regulates myeloid cell function in rheumatoid arthritis. Ann Rheum Dis 2003;62:101-2.</p><p>Jarrett S.J., Cunnane G., Conaghan Ph.G. et al. Anti-tumor necrosis factor-a therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-91.</p><p>Ramos-Casals M., Brito-Zern P., Cuadrado M.J., Khamashta M.A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008;10:442-8.</p><p>Fournier A., Nony A., Rifard K. Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis. Nephrol Ther 2009;May 29 [Epub ahead of print].</p></div><br />


Для цитирования:


Doroshkevich I.A., Муравьев Ю.В. ЛЕЙКОЦИТОКЛАСТИЧЕСКИЙ ВАСКУЛИТ,СВЯЗАННЫЙ С ЛЕЧЕНИЕМ АДАЛИМУМАБОМБОЛЬНОГО АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ. Научно-практическая ревматология. 2010;48(3):88-91. https://doi.org/10.14412/1995-4484-2010-449

For citation:


Doroshkevich I.A., Muravyev Yu.V. LEUKOCYTOCLASTIC VASCULITIS ASSOCIATED WITH ADALIMUMAB TREATMENTIN A PATIENT WITH ANKYLOSING SPONDYLITIS. Rheumatology Science and Practice. 2010;48(3):88-91. (In Russ.) https://doi.org/10.14412/1995-4484-2010-449

Просмотров: 568


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)